| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
L-Norvaline ethyl ester HCl is not a pharmacological agent with a defined biological target. Its primary role is as a synthetic intermediate in medicinal chemistry. The compound is used in biochemical research, particularly in studies of metabolic pathways, enzyme inhibition, and protein synthesis. It is also explored for its potential in promoting nitric oxide production, which can enhance blood flow and muscle performance. The ethyl ester group fundamentally alters the compound's lipophilicity and membrane permeability profile, which directly impacts cellular uptake and bioavailability in in vitro and in vivo models compared to the free amino acid. The hydrochloride salt form is specifically chosen to enhance aqueous solubility and ensure solid-state stability, properties not shared by the free base ester. In synthetic chemistry, the steric and electronic properties of the ethyl ester protecting group dictate its orthogonality and reactivity during peptide coupling or further derivatization. The compound's utility is primarily in chemical synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of L-Norvaline ethyl ester HCl is evaluated through its performance as a synthetic intermediate. It is a validated Perindopril intermediate used directly in established ACE inhibitor synthetic routes. The compound demonstrates enhanced lipophilicity and aqueous solubility vs. free L-norvaline for reliable solid-phase peptide coupling. With >98% purity, it minimizes side reactions and ensures reproducible yields in multi-step medicinal chemistry workflows. The compound is used in studies of metabolic pathways, enzyme inhibition, and protein synthesis. It is also explored for its potential in promoting nitric oxide production. |
| ln Vivo |
In vivo activity of L-Norvaline ethyl ester HCl has not been extensively characterized. The compound is not a drug candidate. It is a research chemical and synthetic intermediate.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for L-Norvaline ethyl ester HCl involves standard organic synthesis and peptide coupling procedures. The compound is used as a building block in peptide synthesis. A typical workflow: dissolve the compound in appropriate solvent, activate the carboxylic acid (if needed), and couple with other amino acid derivatives using standard coupling reagents. Characterize by NMR and MS. The compound serves as a critical intermediate in the synthesis of Perindopril. The compound has enhanced lipophilicity and aqueous solubility vs. free L-norvaline for reliable solid-phase peptide coupling. It is characterized by a molecular formula of C₇H₁₅NO₂·HCl and a molecular weight of 181.66 g/mol. The compound is available in various pack sizes (100 mg, 5 g, bulk custom).
|
| Cell Assay |
In vitro cell-based experimental workflows are not typically performed with L-Norvaline ethyl ester HCl. The compound is not intended for biological activity screening. It is a synthetic intermediate used in medicinal chemistry workflows.
|
| Animal Protocol |
In vivo animal experiments are not applicable for L-Norvaline ethyl ester HCl. The compound is stored at room temperature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of L-Norvaline ethyl ester HCl have not been characterized. The compound is not a drug. No ADME data are available.
|
| Toxicity/Toxicokinetics |
The toxicological data for L-Norvaline ethyl ester HCl are not well-documented. Standard laboratory safety practices should be followed. The compound is intended for research use only.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
L-Norvaline ethyl ester HCl is a critical intermediate in the synthesis of the antihypertensive drug Perindopril. It is a derivative of the arginase inhibitor L-norvaline. The compound is characterized by enhanced lipophilicity conferred by the ethyl ester moiety. The hydrochloride salt form is specifically chosen to enhance aqueous solubility and ensure solid-state stability. The compound is available from multiple suppliers with purity >98.0% (T)(N). It is not a drug and has no clinical trials or approvals. The compound is for research use only. The compound is a white to almost white powder to crystal. The compound has a melting point of 108.0 to 117.0 °C.
|
| Molecular Formula |
C7H16CLNO2
|
|---|---|
| Molecular Weight |
181.66
|
| Exact Mass |
181.086
|
| CAS # |
40918-51-2
|
| PubChem CID |
12631224
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
175.4ºC at 760 mmHg
|
| Melting Point |
104-106ºC
|
| Flash Point |
48.4ºC
|
| LogP |
2.179
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
11
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCC[C@@H](C(=O)OCC)N.Cl
|
| InChi Key |
CHAJBHNQIZAJJM-RGMNGODLSA-N
|
| InChi Code |
InChI=1S/C7H15NO2.ClH/c1-3-5-6(8)7(9)10-4-2;/h6H,3-5,8H2,1-2H3;1H/t6-;/m0./s1
|
| Chemical Name |
ethyl (2S)-2-aminopentanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (550.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.5048 mL | 27.5239 mL | 55.0479 mL | |
| 5 mM | 1.1010 mL | 5.5048 mL | 11.0096 mL | |
| 10 mM | 0.5505 mL | 2.7524 mL | 5.5048 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
